-+ 0.00%
-+ 0.00%
-+ 0.00%

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Invest In Growth?

Simply Wall St·11/18/2026 10:02:57
Listen to the news

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.

Given this risk, we thought we'd take a look at whether Atara Biotherapeutics (NASDAQ:ATRA) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

Does Atara Biotherapeutics Have A Long Cash Runway?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at September 2026, Atara Biotherapeutics had cash of US$9.9m and no debt. Importantly, its cash burn was US$13m over the trailing twelve months. So it had a cash runway of approximately 9 months from September 2026. That's quite a short cash runway, indicating the company must either reduce its annual cash burn or replenish its cash. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
NasdaqGS:ATRA Debt to Equity History November 18th 2026

See our latest analysis for Atara Biotherapeutics

How Well Is Atara Biotherapeutics Growing?

Atara Biotherapeutics managed to reduce its cash burn by 81% over the last twelve months, which suggests it's on the right flight path. In contrast, however, operating revenue fell by 97% during that same period. Starkly suboptimal! In light of the data above, we're fairly sanguine about the business growth trajectory. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

How Hard Would It Be For Atara Biotherapeutics To Raise More Cash For Growth?

Since Atara Biotherapeutics revenue has been falling, the market will likely be considering how it can raise more cash if need be. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Atara Biotherapeutics' cash burn of US$13m is about 20% of its US$64m market capitalisation. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's operations, shareholders would suffer some costly dilution.

So, Should We Worry About Atara Biotherapeutics' Cash Burn?

Even though its falling revenue makes us a little nervous, we are compelled to mention that we thought Atara Biotherapeutics' cash burn reduction was relatively promising. Summing up, we think the Atara Biotherapeutics' cash burn is a risk, based on the factors we mentioned in this article. Taking a deeper dive, we've spotted 5 warning signs for Atara Biotherapeutics you should be aware of, and 3 of them are a bit unpleasant.

Of course Atara Biotherapeutics may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.